Journal: NPJ Vaccines
Article Title: Recovery from antibody-mediated biliary ductopenia and multiorgan inflammation after COVID-19 vaccination
doi: 10.1038/s41541-024-00861-9
Figure Lengend Snippet: Hemogram ( A ), kidney ( B ), liver ( C ), pancreas ( D ), inflammation ( E ), and antibodies (anti-SARS-CoV-2 Spike antibody & angiotensin II receptor type 1 (AT1R) antibody) ( F ). Day 0 is the date of admission and doses and duration of medications are at top. Improvement was noted after starting steroids and plasma exchange (D7). Hb drop was noted after liver biopsy (D5). Reference of positivity: anti-SARS-CoV-2 Spike antibody (≥0.8 U/mL, quantitative Roche Elecsys® Anti-SARS-CoV-2 S assay), angiotensin II receptor type 1 (AT1R) antibody (>17 U/mL, enzyme immuno-assay (EIA), CellTrend GmbH). Normal ranges of laboratory testes other than antibodies were presented in Supplementary Table . ALT alanine transaminase, AST aspartate transaminase, BUN blood urea nitrogen, Cre creatinine, CRP C-reactive protein, D-bil direct bilirubin, Hb hemoglobin, PLT platelet, T-bil total bilirubin, WBC white blood cell.
Article Snippet: In this case, we observed a decreasing trend in the anti-SARS-CoV-2 spike antibody level (peak, 12,371 BAU/mL on day 32; positive, ≥0.8 BAU/mL), the vaccine-induced antibodies against the viral spike protein, measured using a quantitative Roche Elecsys® Anti-SARS-CoV-2 S assay (Fig. ).
Techniques: Medications, Immuno Assay